Please upgrade your browser.
A class of cutting-edge cancer drugs could keep patients alive for much longer than they do now following a major new discovery about exactly how they attack tumours.
The neutrophil-lymphocyte ratio (NLR) is an indicator of the systemic inflammatory response.
Survival rates much better in neighbouring countries than at home
New evidence suggests that three-dimensional pathological tumor volume (TV) provides additional prognostic information in renal cell carcinoma (RCC) to that provided by tumor size alone.
...watch a video about our peer review process & apply for a YIA.
Certain nanoparticles (NP) emit heat energy when excited by near-infrared (NIR) laser energy. We determined efficacy of a novel nanoparticle to induce hyperthermic cellular death of renal cell carcinoma in vitro.
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance.
Osteosarcoma cells expressing high levels of VEGFR1...
Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line RCC Treatment
The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC).
mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.
|NeonCRM by Neon One|